Provided by Tiger Trade Technology Pte. Ltd.

Vor Biopharma Inc.

22.71
-0.6500-2.78%
Post-market: 22.710.00000.00%19:30 EDT
Volume:500.00K
Turnover:11.31M
Market Cap:1.34B
PE:1.97
High:23.18
Open:23.12
Low:21.90
Close:23.36
52wk High:50.20
52wk Low:6.50
Shares:59.16M
Float Shares:37.23M
Volume Ratio:0.61
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):11.53
EPS(LYR):-70.5015
ROE:-125.43%
ROA:-21.37%
PB:-6.71
PE(LYR):-0.32

Loading ...

Vor Biopharma shareholders approved amended 2021 equity incentive plan at annual meeting

Reuters
·
Jun 13

Vor Bio gains boost from telitacicept IgA nephropathy approval

TIPRANKS
·
Jun 09

Vor Bio Partner Drug Earns Regulatory Approval In China For Sjogren's Disease

MT Newswires Live
·
Jun 08

Vor Bio says China NMPA approves telitacicept for Sjögren’s disease

Reuters
·
Jun 08

Vor Bio says telitacicept wins China conditional approval for IgA nephropathy

Reuters
·
Jun 08

Telitacicept Receives Nmpa Conditional Approval for the Treatment of Iga Nephropathy in China

THOMSON REUTERS
·
Jun 08

Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar

TIPRANKS
·
Jun 05

Vor Bio grants 61,050 stock options, 12,900 RSUs to new hires under inducement plan

Reuters
·
Jun 02

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 02

Vor Biopharma Price Target Maintained With a $31.00/Share by HC Wainwright & Co.

Dow Jones
·
May 19

Vor Bio price target raised to $18 from $15 at Wedbush

TIPRANKS
·
May 15

Vor Biopharma Is Maintained at Neutral by Wedbush

Dow Jones
·
May 14

Wedbush Adjusts Price Target on Vor Biopharma to $18 From $15, Maintains Neutral Rating

MT Newswires Live
·
May 14

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Halozyme (HALO) and Vor Biopharma (VOR)

TIPRANKS
·
May 14

Vor Biopharma Q1 Adj. EPS $(0.73) Beats $(0.78) Estimate

Benzinga Earnings
·
May 13

Earnings Flash (VOR) Vor Biopharma Posts Q1 Net Loss $5.11 a Share, vs. FactSet Est of $0.78 Loss

MT Newswires Live
·
May 13

Vor Biopharma Q1 net loss widens

Reuters
·
May 13

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 13

Vor Biopharma Q1 Net Income USD -219.6 Million VS. Ibes Estimate USD -32.8 Million

THOMSON REUTERS
·
May 13

Hisense Mulakan Kempen FIFA World Cup 2026™, Dekatkan Peminat Dengan "Menginovasi Kehidupan Lebih Cerah"

prnewswire
·
May 11